The breach between the biological impact of HER2 amplification versus mutation is further highlighted by the observation that the former has been associated with improved response to EGFR inhibition in NSCLC, whereas the latter has been linked to in vitro resistance to EGFR tyrosine kinase inhibitors (TKIs) [28,29]. Here, ERBB2 is linked to non-small cell lung carcinoma.